Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Collaborative Health Research Projects

University of Toronto

$183,900.00

Combination strategies to promote repair and functional recovery following stroke

FY 2022-23

Summary
In Canada, it is estimated that stroke costs the Canadian economy almost $3 billion per year.Stem cell based therapies hold great promise for the treatment of stroke. This research willlay the foundation for clinical approaches to treat stroke by addressing current challenges withcell based therapies. Our team of researchers and industry partner will take advantage ofinnovations in stem cell biology, cell transplantation, and bioengineering to promote bothtissue and functional repair in preclinical models of stroke. Our measures of success arefunctional assays undoubtedly the most relevant outcome for translation. Wewill perform our studies in chronic stroke models, as chronic stroke has been less well studieddespite the serious impacts including premature death, poor quality of life and large adverseeconomic effects on families, communities and society in general. With the goal of developingclinically relevant strategies to treat the stroke-injured brain we will combine a novel,proprietary human cell source engineered by our industry partner, that permits patient specificcells to be used for cell transplantation. These cells are outside of ethical concerns and ableto avoid rejection after transplantation. Importantly, the cells are designed to only make brainspecific cells so will not form inappropriate cell types following transplantation. We willcombine the cell transplantation with novel bioengineered tools to deliver drugs that promotebrain plasticity and cell survival by reducing the negative environmental factors found in theinjured brain. Further, to enhance cell survival - a significant challenge for cell basedtherapies - our preclinical studies will utilize a novel, patented drug that inhibits cell death.Together, these preclinical studies using combinatorial strategies will set the stage for clinicaltrials to treat stroke.
Program
Collaborative Health Research Projects
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data

As published

Application id
549672-2020
Name nom
Morshead, Cindi M
Department département
Donnelly Centre for Cellular & Biomolecular Research
Organization id
31
Institution établissement
University of Toronto
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2022
Competition year année de concours
2020
Award amount
183900
Program id
CHRPJ
Program name en
Collaborative Health Research Projects
Program name fr
Projets de recherche concertée sur la santé
Group en
RESEARCH PARTNERSHIPS
Group fr
PARTENARIATS DE RECHERCHE
Committee code
360
Committee name en
Collaborative Health Research Projects Selection Panel
Committee name fr
Comité de sélection de projets de recherche concertée sur la santé
Area of application code
9999
Area of application group en
Not available
Area of application group fr
Non disponible
Area of application en
Not available
Area of application fr
Non disponible
Research subject code
5100
Research subject group en
Cell biology
Research subject group fr
Biologie cellulaire
Research subject en
Cell biology
Research subject fr
Biologie cellulaire
Installment
inst:3
Partie
1
Nb partie
3
Application title
Combination strategies to promote repair and functional recovery following stroke
Application summary
In Canada, it is estimated that stroke costs the Canadian economy almost $3 billion per year.Stem cell based therapies hold great promise for the treatment of stroke. This research willlay the foundation for clinical approaches to treat stroke by addressing current challenges withcell based therapies. Our team of researchers and industry partner will take advantage ofinnovations in stem cell biology, cell transplantation, and bioengineering to promote bothtissue and functional repair in preclinical models of stroke. Our measures of success arefunctional assays undoubtedly the most relevant outcome for translation. Wewill perform our studies in chronic stroke models, as chronic stroke has been less well studieddespite the serious impacts including premature death, poor quality of life and large adverseeconomic effects on families, communities and society in general. With the goal of developingclinically relevant strategies to treat the stroke-injured brain we will combine a novel,proprietary human cell source engineered by our industry partner, that permits patient specificcells to be used for cell transplantation. These cells are outside of ethical concerns and ableto avoid rejection after transplantation. Importantly, the cells are designed to only make brainspecific cells so will not form inappropriate cell types following transplantation. We willcombine the cell transplantation with novel bioengineered tools to deliver drugs that promotebrain plasticity and cell survival by reducing the negative environmental factors found in theinjured brain. Further, to enhance cell survival - a significant challenge for cell basedtherapies - our preclinical studies will utilize a novel, patented drug that inhibits cell death.Together, these preclinical studies using combinatorial strategies will set the stage for clinicaltrials to treat stroke.